Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182640 | 1.00 | CA12 (0.53) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL16931022 | 0.81 | ACP3 (0.63) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL7914114 | 0.80 | CA1 (0.45) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL5747021 | 0.79 | GRM8 (0.55) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL15226777 | 0.79 | GRM8 (0.55) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL735221 | 0.77 | CA1 (0.53) | CA12MMP2CA1MMP9MMP8 | |
| Phosphoric Acid SCHEMBL28639141 | 0.77 | CA1 (0.65) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL1774643 | 0.77 | ALDH1A1 (0.42) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL3230188 | 0.76 | CA12 (0.51) | CA12MMP2CA1MMP9MMP8 | |
| SCHEMBL1317230 | 0.76 | ALDH1A1 (0.59) | CA12CA1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438056-B1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS LLC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110224096-A1 | FLUORESCENT PHOSPHONIC ESTER LIBRARY | TECHNISCHE UNIVERSITAT GRAZ (AT) | 2011-09-15 | — | — | US | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
| US-20080108508-A1 | Fluorescent Phosphonic Ester Library | TECHNISCHE UNIVERSITÄT GRAZ (AT) | 2008-05-08 | — | — | US | disclosed |
| EP-1771735-A1 | FLUORESCENT PHOSPHONIC ESTER LIBRARY | Technische Universität Graz (AT) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010403-A1 | FLUORESCENT PHOSPHONIC ESTER LIBRARY | TECHNISCHE UNIVERSITÄT GRAZ (AT) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | CA12 4611/4885MMP2 4375/4885CA1 4413/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CA12 4866/4885MMP2 2634/4885CA1 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.